MULTIMODAL IMAGING AND LONG-TERM TREATMENT OUTCOMES OF RELENTLESS PLACOID CHORIORETINITIS.

Area of Science:

• Ophthalmology
• Retinal Diseases
• Immunosuppressive Therapy

Background:

• Relentless placoid chorioretinitis (RPC) is a rare condition lacking standardized treatment guidelines.
• Long-term immunosuppressive therapy (IMT) is often required for RPC management.

Purpose of the Study:

• To report outcomes from the largest single-institution cohort of patients diagnosed with RPC.
• To evaluate the effectiveness of various immunosuppressive agents in RPC treatment.

Main Methods:

• Retrospective cohort study of 8 patients (11 eyes) with RPC.
• Analysis of initial treatments including oral prednisone, topical steroids, methotrexate, and cyclosporine.
• Review of patient data from January 2015 to January 2024.

Main Results:

• All patients achieved disease control with no active lesions on final follow-up.
• Visual acuity improved or remained stable in all eyes (mean improvement of 3.4 lines).
• Methotrexate treatment showed significant visual acuity improvement (mean 6 lines).

Conclusions:

• This study represents the largest cohort of RPC patients published to date.
• Multimodal imaging and multidisciplinary care are crucial for managing RPC.
• Immunosuppressive therapy, particularly methotrexate, can lead to favorable outcomes in RPC.